J&J/Boston Scientific stent patent suit update
This article was originally published in The Gray Sheet
Executive Summary
Federal appeals court upholds lower court ruling that Johnson & Johnson's Cypher and Bx Velocity stent systems infringe a valid Boston Scientific patent, and that Boston Scientific's Taxus, Express and Liberte stents infringe a valid J&J patent. Liberte also infringes a second valid J&J patent, the court affirmed. However, the court also overturned an infringement ruling against Liberte. "Damages will be determined in a future court proceeding," Boston Scientific notes in a March 31 release
You may also be interested in...
Takeda, Astellas Found New JV To Support Japanese Bioventures
Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.
Could Eledon’s Anti-CD40L Change Transplant Medicine?
Eledon Pharmaceuticals’ CD40 Ligand blocker has yielded impressive results for post-transplant immunosuppression and cutting-edge transplant doctors have also used it for pig-to-human kidney and heart transplants, opening up the field of xenotransplantation.
Turning That Frown Upside Down: Treating Depression With Facial Botox Injections
In this episode of the In Vivo podcast, Eric Finzi, CEO of Healis Therapeutics, discusses how his company is targeting major depression, post-traumatic stress disorder and other mental illnesses using facial botox injections.